DOP2015000244A - Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) - Google Patents
Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)Info
- Publication number
- DOP2015000244A DOP2015000244A DO2015000244A DO2015000244A DOP2015000244A DO P2015000244 A DOP2015000244 A DO P2015000244A DO 2015000244 A DO2015000244 A DO 2015000244A DO 2015000244 A DO2015000244 A DO 2015000244A DO P2015000244 A DOP2015000244 A DO P2015000244A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- cancer
- functional
- ret
- thyroid
- disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000001890 transfection Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 7
- 201000011510 cancer Diseases 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 210000001685 thyroid gland Anatomy 0.000 abstract 2
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 abstract 1
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 abstract 1
- 206010004593 Bile duct cancer Diseases 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 230000003187 abdominal effect Effects 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003325 follicular Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004899 motility Effects 0.000 abstract 1
- 210000003200 peritoneal cavity Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 abstract 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013072683 | 2013-03-15 | ||
| CN2013090059 | 2013-12-20 | ||
| CN2014072449 | 2014-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2015000244A true DOP2015000244A (es) | 2015-12-31 |
Family
ID=50390154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2015000244A DOP2015000244A (es) | 2013-03-15 | 2015-09-15 | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US9382238B2 (OSRAM) |
| EP (1) | EP2970191B1 (OSRAM) |
| JP (1) | JP2016516026A (OSRAM) |
| CN (1) | CN105051027A (OSRAM) |
| AU (1) | AU2014229233B2 (OSRAM) |
| BR (1) | BR112015023618A2 (OSRAM) |
| CA (1) | CA2905627A1 (OSRAM) |
| CL (1) | CL2015002514A1 (OSRAM) |
| CR (1) | CR20150490A (OSRAM) |
| CY (1) | CY1118730T1 (OSRAM) |
| DK (1) | DK2970191T3 (OSRAM) |
| DO (1) | DOP2015000244A (OSRAM) |
| EA (1) | EA029296B1 (OSRAM) |
| ES (1) | ES2616655T3 (OSRAM) |
| HR (1) | HRP20170363T1 (OSRAM) |
| HU (1) | HUE033423T2 (OSRAM) |
| IL (1) | IL241161A0 (OSRAM) |
| LT (1) | LT2970191T (OSRAM) |
| ME (1) | ME02664B (OSRAM) |
| MX (1) | MX2015012286A (OSRAM) |
| NZ (1) | NZ628388A (OSRAM) |
| PE (1) | PE20151538A1 (OSRAM) |
| PH (1) | PH12015502044A1 (OSRAM) |
| PL (1) | PL2970191T3 (OSRAM) |
| PT (1) | PT2970191T (OSRAM) |
| RS (1) | RS55710B1 (OSRAM) |
| SG (1) | SG11201506695UA (OSRAM) |
| SI (1) | SI2970191T1 (OSRAM) |
| SM (1) | SMT201700152T1 (OSRAM) |
| TW (1) | TW201524958A (OSRAM) |
| UA (1) | UA115264C2 (OSRAM) |
| UY (1) | UY35465A (OSRAM) |
| WO (1) | WO2014141187A1 (OSRAM) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2628418T3 (es) | 2010-05-20 | 2017-08-02 | Array Biopharma, Inc. | Compuestos macrocíclicos como inhibidores de la TRK cinasa |
| US20170283404A1 (en) * | 2014-09-08 | 2017-10-05 | Glaxosmithkline Intellectual Property Development Limited | Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide |
| PT3191450T (pt) * | 2014-09-10 | 2019-05-29 | Glaxosmithkline Ip Dev Ltd | Derivados de piridona como inibidores da quinase rearranjada durante a transfecção (ret) |
| EA032030B1 (ru) | 2014-09-10 | 2019-03-29 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| RS61485B1 (sr) | 2015-07-16 | 2021-03-31 | Array Biopharma Inc | Supstituisana pirazolo [1,5-a] piridinska jedinjenja kao inhibitori ret kinaze |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| IL302209B2 (en) | 2015-11-02 | 2024-06-01 | Blueprint Medicines Corp | Inhibitors of ret |
| WO2017145050A1 (en) | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer |
| ES2904615T3 (es) * | 2016-03-16 | 2022-04-05 | Plexxikon Inc | Compuestos y métodos para la modulación de quinasas e indicaciones al respecto |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| CN109996556A (zh) | 2016-05-13 | 2019-07-09 | 分子医学研究院 | 治疗与ilc3细胞相关之疾病的方法 |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| JP2018052878A (ja) | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| EP3571203B1 (en) | 2017-01-18 | 2023-06-07 | Array BioPharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN110891573A (zh) | 2017-05-15 | 2020-03-17 | 缆图药品公司 | Ret抑制剂和mtorc1抑制剂的组合及其用于治疗由异常ret活性介导的癌症的用途 |
| US10093648B1 (en) * | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
| TWI876442B (zh) * | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
| PT3773589T (pt) | 2018-04-03 | 2024-02-06 | Blueprint Medicines Corp | Inibidor de ret para utilização no tratamento de cancro com alteração de ret |
| CN109096264B (zh) * | 2018-08-28 | 2019-08-23 | 山东理工职业学院 | Ret抑制剂及其制备方法、组合物和用途 |
| JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物 |
| EP3956330A4 (en) | 2019-04-18 | 2023-01-18 | The Johns Hopkins University | SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE |
| JP7461605B2 (ja) * | 2020-02-20 | 2024-04-04 | 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 | キノリン系化合物 |
| AR121914A1 (es) * | 2020-04-27 | 2022-07-20 | Lilly Co Eli | Compuestos útiles para inhibir la quinasa ret |
| CA3183728A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CN115803316B (zh) * | 2020-07-23 | 2024-12-06 | 深圳晶泰科技有限公司 | 吡啶酮类化合物及其制备方法和应用 |
| TWI790810B (zh) | 2020-11-06 | 2023-01-21 | 美商美國禮來大藥廠 | Ret激酶抑制劑 |
| CA3222177A1 (en) | 2021-06-03 | 2022-12-08 | Fundacao D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud | Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit |
| CN115626880B (zh) * | 2022-11-15 | 2023-11-14 | 常州大学 | 3-硝基-5-氰基三氟甲苯的合成方法 |
| CN116925023B (zh) * | 2023-07-18 | 2025-11-21 | 江苏桐孚高新材料有限公司 | 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法 |
| EP4650002A1 (en) * | 2024-05-15 | 2025-11-19 | Ludwig-Maximilians-Universität | Aniline-based modulators of the nuclear receptor tlx (nr2e1) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK1812002A3 (en) | 1999-08-12 | 2003-02-04 | Pharmacia Italia Spa | 3(5)-Amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| AU2002215053A1 (en) * | 2000-11-27 | 2002-06-24 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| DE10201764A1 (de) | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| JP2010506879A (ja) * | 2006-10-16 | 2010-03-04 | ノバルティス アーゲー | プロテインキナーゼ阻害剤として有用なフェニルアセトアミド |
| WO2008058341A1 (en) * | 2006-11-15 | 2008-05-22 | Cytopia Research Pty Ltd | Inhibitors of kinase activity |
| WO2011022473A1 (en) * | 2009-08-19 | 2011-02-24 | Ambit Biosciences Corporation | Biaryl compounds and methods of use thereof |
| US9073895B2 (en) | 2010-12-16 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| US8937071B2 (en) | 2013-03-15 | 2015-01-20 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
-
2014
- 2014-03-14 PT PT147135982T patent/PT2970191T/pt unknown
- 2014-03-14 PL PL14713598T patent/PL2970191T3/pl unknown
- 2014-03-14 US US14/775,772 patent/US9382238B2/en not_active Expired - Fee Related
- 2014-03-14 LT LTEP14713598.2T patent/LT2970191T/lt unknown
- 2014-03-14 SI SI201430170A patent/SI2970191T1/sl unknown
- 2014-03-14 UA UAA201510041A patent/UA115264C2/uk unknown
- 2014-03-14 MX MX2015012286A patent/MX2015012286A/es unknown
- 2014-03-14 AU AU2014229233A patent/AU2014229233B2/en not_active Ceased
- 2014-03-14 WO PCT/IB2014/059817 patent/WO2014141187A1/en not_active Ceased
- 2014-03-14 EP EP14713598.2A patent/EP2970191B1/en active Active
- 2014-03-14 CA CA2905627A patent/CA2905627A1/en not_active Abandoned
- 2014-03-14 SM SM20170152T patent/SMT201700152T1/it unknown
- 2014-03-14 NZ NZ628388A patent/NZ628388A/en not_active IP Right Cessation
- 2014-03-14 HU HUE14713598A patent/HUE033423T2/en unknown
- 2014-03-14 ES ES14713598.2T patent/ES2616655T3/es active Active
- 2014-03-14 CN CN201480015907.3A patent/CN105051027A/zh active Pending
- 2014-03-14 ME MEP-2017-60A patent/ME02664B/me unknown
- 2014-03-14 PE PE2015001878A patent/PE20151538A1/es not_active Application Discontinuation
- 2014-03-14 RS RS20170177A patent/RS55710B1/sr unknown
- 2014-03-14 EA EA201591738A patent/EA029296B1/ru not_active IP Right Cessation
- 2014-03-14 JP JP2015562529A patent/JP2016516026A/ja active Pending
- 2014-03-14 DK DK14713598.2T patent/DK2970191T3/en active
- 2014-03-14 TW TW103109315A patent/TW201524958A/zh unknown
- 2014-03-14 BR BR112015023618A patent/BR112015023618A2/pt not_active IP Right Cessation
- 2014-03-14 HR HRP20170363TT patent/HRP20170363T1/hr unknown
- 2014-03-14 UY UY0001035465A patent/UY35465A/es unknown
- 2014-03-14 SG SG11201506695UA patent/SG11201506695UA/en unknown
-
2015
- 2015-09-03 IL IL241161A patent/IL241161A0/en unknown
- 2015-09-08 CL CL2015002514A patent/CL2015002514A1/es unknown
- 2015-09-10 PH PH12015502044A patent/PH12015502044A1/en unknown
- 2015-09-14 CR CR20150490A patent/CR20150490A/es unknown
- 2015-09-15 DO DO2015000244A patent/DOP2015000244A/es unknown
-
2016
- 2016-06-02 US US15/171,229 patent/US9789100B2/en not_active Expired - Fee Related
-
2017
- 2017-03-14 CY CY20171100319T patent/CY1118730T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2015000244A (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) | |
| CO2017002378A2 (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) | |
| EA201790546A1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
| AR095308A1 (es) | Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento | |
| RU2016102158A (ru) | Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака | |
| EA201992418A1 (ru) | Бициклические соединения и их применение в лечении рака | |
| EA201492004A1 (ru) | Органические композиции для лечения kras-ассоциированных заболеваний | |
| JP2017514806A5 (OSRAM) | ||
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| PH12021552973A1 (en) | Methods of treating urinary system cancers | |
| EA201992130A1 (ru) | Usl-1 для применения в лечении злокачественной опухоли | |
| RU2015127037A (ru) | Комбинации ингибитора pi3k/akt с ингибитором her3/egfr и способы их применения | |
| TH158993A (th) | อนุพันธ์ไพริดีนในรูปสารยับยั้งไคเนสถูกจัดเรียงใหม่ในระหว่างการทรานส์เฟคชั่น (ret) | |
| EA202193346A1 (ru) | Способы лечения злокачественных опухолей мочевыделительной системы | |
| AR101801A1 (es) | Compuestos de benzamida y acetamida, sales farmacéuticamente aceptables de los mismos, composición farmacéutica que los comprende y su uso para la preparación de un medicamento | |
| Qi et al. | Effects of Different Doses of Bevacizumab on Irinotecan Distribution in Nude Mice Bearing Human Colon Cancer Cell Xenografts | |
| Wael et al. | Management of posterior fossa medulloblastoma in adults | |
| Morcillo et al. | PO-0693 RADICAL RADIOTHERAPY IN LOCALIZED PROSTATE CANCER. LONG TERM RESULTS |